Heather M. O'Hagan

Dr. Heather M. O'Hagan

Indiana University School of Medicine, Indianapolis, Indiana, USA
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2011 in Cancer Cell
Verified
Journal Article
Closed access
HOHeather M. O'Hagan
Heather M. O'Hagan
WWWei Wang
Wei Wang
SSSubhojit Sen
Subhojit Sen
CSChristina DeStefano Shields
Christina DeStefano Shields
SLStella S. Lee
Stella S. Lee
SBStephen B. Baylin
Stephen B. Baylin

15 August 2008 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
HOHeather M. O'Hagan
Heather M. O'Hagan
HMHelai P Mohammad
Helai P Mohammad
SBStephen B. Baylin
Stephen B. Baylin
Chronic exposure to inducers of DNA base oxidation and single and double strand breaks contribute to tumorigenesis. In addition to the genetic changes caused by this DNA damage, such tumors often contain epigenetically silenced genes with aberrant promoter region CpG island DNA hypermethylation. We herein explore the relationships between such DNA damage and epigenetic gene silencing using an experimental model in which we induce a defined double strand break in an exogenous promoter construct of the E-cadherin CpG island, which is frequently aberrantly DNA hypermethylated in epithelial cancers. Following the onset of repair of the break, we observe recruitment to the site of damage of key proteins involved in establishing and maintaining transcriptional repression, namely SIRT1, EZH2, DNMT1, and DNMT3B, and the appearance of the silencing histone modifications, hypoacetyl H4K16, H3K9me2 and me3, and H3K27me3. Although in most cells selected after the break, DNA repair occurs faithfully with preservation of activity of the promoter, a small percentage of the plated cells demonstrate induction of heritable silencing. The chromatin around the break site in such a silent clone is enriched for most of the above silent chromatin proteins and histone marks, and the region harbors the appearance of increasing DNA methylation in the CpG island of the promoter. During the acute break, SIRT1 appears to be required for the transient recruitment of DNMT3B and subsequent methylation of the promoter in the silent clones. Taken together, our data suggest that normal repair of a DNA break can occasionally cause heritable silencing of a CpG island–containing promoter by recruitment of proteins involved in silencing. Furthermore, with contribution of the stress-related protein SIRT1, the break can lead to the onset of aberrant CpG island DNA methylation, which is frequently associated with tight gene silencing in cancer. Human cancers contain epigenetic changes as well as DNA mutations that play a role in abnormal silencing of tumor suppressor genes. In contrast to DNA mutations that change the sequence of DNA, epigenetic changes cause abnormal silencing of genes through DNA methylation via the addition of methyl groups to DNA and through modifications to the associated chromatin proteins. One important event in tumor initiation and progression is the exposure of cells to DNA damage during events such as chronic inflammation and carcinogen exposure. We hypothesized that such damage may play a role in producing chromatin alterations, which could initiate epigenetic silencing of tumor suppressor genes. Here we show, using an exogenous gene promoter model, that key proteins involved in epigenetic silencing are recruited to the DNA near a double strand break. Occasionally, sustained localization of these proteins to the gene promoter leads to silencing of the associated gene and to the seeding and spreading of DNA methylation within the promoter that further stabilizes the silencing. This finding suggests that DNA damage may directly contribute to the large number of epigenetically silenced genes in tumors.

25 May 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
SMSamuel A. Miller
Samuel A. Miller
RPRobert A. Policastro
Robert A. Policastro
SSShruthi Sriramkumar
Shruthi Sriramkumar
TLTim Lai
Tim Lai
THThomas D. Huntington
Thomas D. Huntington
HOHeather M. O'Hagan
Heather M. O'Hagan
Despite the connection of secretory cells, including goblet and enteroendocrine (EEC) cells, to distinct mucus-containing colorectal cancer histologic subtypes, their role in colorectal cancer progression has been underexplored. Here, our analysis of The Cancer Genome Atlas (TCGA) and single-cell RNA-sequencing data demonstrates that EEC progenitor cells are enriched in BRAF-mutant colorectal cancer patient tumors, cell lines, and patient-derived organoids. In BRAF-mutant colorectal cancer, EEC progenitors were blocked from differentiating further by DNA methylation and silencing of NEUROD1, a key gene required for differentiation of intermediate EECs. Mechanistically, secretory cells and the factors they secrete, such as trefoil factor 3, promoted colony formation and activation of cell survival pathways in the entire cell population. Lysine-specific demethylase 1 (LSD1) was identified as a critical regulator of secretory cell specification in vitro and in a colon orthotopic xenograft model, where LSD1 loss blocks formation of EEC progenitors and reduces tumor growth and metastasis. These findings reveal an important role for EEC progenitors in supporting colorectal cancer. Significance: This study establishes enteroendocrine progenitors as a targetable population that promotes BRAF-mutant colorectal cancer and can be blocked by LSD1 inhibition to suppress tumor growth.

30 July 2018 in Cancers
Verified
Journal Article
Open access
PDF file
SSSudha Savant
Sudha Savant
SSShruthi Sriramkumar
Shruthi Sriramkumar
HOHeather M. O'Hagan
Heather M. O'Hagan
Inflammation plays a role in the initiation and development of many types of cancers, including epithelial ovarian cancer (EOC) and high grade serous ovarian cancer (HGSC), a type of EOC. There are connections between EOC and both peritoneal and ovulation-induced inflammation. Additionally, EOCs have an inflammatory component that contributes to their progression. At sites of inflammation, epithelial cells are exposed to increased levels of inflammatory mediators such as reactive oxygen species, cytokines, prostaglandins, and growth factors that contribute to increased cell division, and genetic and epigenetic changes. These exposure-induced changes promote excessive cell proliferation, increased survival, malignant transformation, and cancer development. Furthermore, the pro-inflammatory tumor microenvironment environment (TME) contributes to EOC metastasis and chemoresistance. In this review we will discuss the roles inflammation and inflammatory mediators play in the development, progression, metastasis, and chemoresistance of EOC.

1 September 2017 in Cancer Cell
Verified
Journal Article
Closed access
MVMichelle Vaz
Michelle Vaz
SHStephen Y. Hwang
Stephen Y. Hwang
IKIoannis Kagiampakis
Ioannis Kagiampakis
JPJillian Phallen
Jillian Phallen
APAshwini Patil
Ashwini Patil
SBStephen B. Baylin
Stephen B. Baylin

1 May 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MARIO D. GALIGNIANAMARIO D. GALIGNIANA
MARIO D. GALIGNIANA
JHJennifer M. Harrell
Jennifer M. Harrell
HOHeather M. O'Hagan
Heather M. O'Hagan
MLMats Ljungman
Mats Ljungman
WPWilliam B. Pratt
William B. Pratt
The tumor suppressor protein p53 is known to be transported to the nucleus along microtubular tracks by cytoplasmic dynein. However, the connection between p53 and the dynein motor protein complex has not been established. Here, we show that hsp90.binding immunophilins link p53.hsp90 complexes to dynein and that prevention of that linkage in vivo inhibits the nuclear movement of p53. First, we show that p53.hsp90 heterocomplexes from DLD-1 human colon cancer cells contain an immunophilin (FKBP52, CyP-40, or PP5) as well as dynein. p53.hsp90.immunophilin.dynein complexes can be formed by incubating immunopurified p53 with rabbit reticulocyte lysate, and we show by peptide competition that the immunophilins link via their tetratricopeptide repeat domains to p53-bound hsp90 and by means of their PPIase domains to the dynein complex. The linkage of immunophilins to the dynein motor is indirect by means of the dynamitin component of the dynein-associated dynactin complex, and we show that purified FKBP52 binds directly by means of its PPIase domain to purified dynamitin. By using a temperature-sensitive mutant of p53 where cytoplasmic-nuclear movement occurs by shift to permissive temperature, we show that p53 movement is impeded when p53 binding to hsp90 is inhibited by the hsp90 inhibitor radicicol. Also, nuclear movement of p53 is inhibited when immunophilin binding to dynein is competed for by expression of a PPIase domain fragment in the same manner as when dynein linkage to cargo is dissociated by expression of dynamitin. This is the first demonstration of the linkage between an hsp90-chaperoned transcription factor and the system for its retrograde movement to the nucleus both in vitro and in vivo.